SGUI Stock UPDATES Sanguine Corporation (SGUI) 0.0350 08/05/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Sanguine Corporation (SGUI) 0.0350 $SGUI

Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products to 2017
M2 - Mon Jun 30, 2:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/45fldn/blood_the) has announced the addition of the "Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products" report to their offering. The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products provides an analysis of all the key market segments involved in this industry, including products, equipment and testing. The global blood industry has experienced strong growth in recent years and although this brisk expansion will slow somewhat as products continue to mature and pricing pressures increase, growth will remain solid though 2017 as a result of aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions and indications; expansion of health coverage in the U.S. via health care reform; and continued strong promotion of blood donation by collection agencies. A variety of infectious agents can be present in blood, including viruses (e.g., HIV-1, hepatitis B and C, HTLV, West Nile virus), bacteria, protozoans, Chagas disease, Lyme Disease and prions (e.g., the agent of variant Crueutzfeldt-Jakob disease, which is the human form of mad cow disease). As of 2013, the main residual risk is due to hepatitis B virus - ranging from 10 in Spain to 1.6 per million donations in France and Germany although other conditions such as variant Creutzfeldt-Jakob disease (vCJD) or HIV may pose high risk in certain regions. Testing markets covered include: - Blood Banking and Plasmapheresis Testing - Blood Typing - Human Immunodeficiency Virus (HIV) Testing - Hepatitis A Virus Testing - Hepatitis B Virus Testing - Hepatitis C Virus Testing - Human T-Cell Leukemia Virus Testing - West Nile Virus Testing - Other Safety Testing Blood products covered in the report include: - Red Blood Cells (RBCs) - Immunoglobulins - Albumin - Other Plasma Products - Synthetic HBOC and PFC Agents - Recombinant Factors Blood equipment revenues and forecasts are provided for: - Blood Collection Equipment - Automated Blood Collection Equipment In addition to complete market data, including forecasts to 2017, the study reports: - Product demand estimates by region - Collection and transfusion estimates - High-blood-loss procedure estimates - Product pricing - Reimbursement rates - Epidemiology of key conditions requiring blood products - Products on the market and in development The report also profiles key companies in the industry, including: - AABB - Abbott Laboratories - America's Blood Centers - American Red Cross - Baxter International - Bio-Rad Laboratories - BioTime Inc. - Gen-Probe Inc. /Hologic - Fenwal/Fresenius Kabi - Grifols Biologicals, Inc. - Novartis Diagnostics - Novo Nordisk A/S - OPK BioTech - Oxygen Biotherapeutics - Perftoran - Roche - Sanguine Corp. For more information visit http://www.researchandmarkets.com/research/45fldn/blood_the

Global Plasma Market 2012-2016 with Baxter International Inc., CSL Behring LLC, Grifols S.A., and Octapharma AG Dominating
M2 - Tue Feb 04, 9:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/lqj4jb/global_plasma) has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. This report forecasts the Global Plasma market to grow at a CAGR of 10.31 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market. Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group. This report Global Plasma Market 2012-2016 is based on an in-depth analysis covering the Americas, the EMEA region, and the APAC region. The report aims to aid decision makers' understanding of the present and future landscape of the market. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the Global Plasma market has been witnessing significant consolidation and as a result the positions of the leading players have shifted dramatically over the past decade. This trend is expected to continue during the forecast period as vendors attempt to strengthen or hold their market position. Market consolidation has resulted in stronger competitors that are better able to compete as sole-source vendors to end-users. For instance, Australia-based CSL Behring has become one of the world's leading fractionators through a series of acquisitions including its 2000 buyout of ZLB Behring and 2004 purchase of Aventis Behring. Grifols acquisition of Talecris Biotherapeutics has further consolidated the industry.' For more information visit http://www.researchandmarkets.com/research/lq...bal_plasma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The Global Plasma Market to Grow At A CAGR Of 10.31 Percent over the Period 2012-2016
M2 - Thu Apr 11, 12:19PM CDT
Research and Markets has announced the addition of the "Global Plasma Market 2012-2016" report to their offering. One of the key factors contributing to this market growth is the increase in the aging population. The Global Plasma market has also been witnessing the trend of increasing market consolidation. However, stringent regulations could pose a challenge to the growth of this market. Key vendors dominating this space CSL Behring LLC, Baxter International Inc., Grifols S.A., and Octapharma AG Other vendors mentioned in the report are Kedrion S.p.A., Biotest AG, Sanguine Corp., Cangene bioPharma Inc., Haemacure Corp., Kamada Inc., Omrix Biopharmaceuticals Inc., Vivostat A/S, Pfizer Inc., AstraZeneca plc, Takeda Pharmaceutical Inc., Novo Nordisk A/S, sanofi S.A., China Biologic Products Inc., Beijing Tiantan Biological Products Co. Ltd., Bharat Serums and Vaccines Ltd., and LFB Group. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''Over the years, the Global Plasma marke



Scroll down for more posts ▼

Top 10 Most Recent News Articles

EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 204

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 127

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 197

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 150

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices

Updated Category News Views 303

Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 309

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 148

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 108

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 268

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Ten-Year Transformation: The Journey of Performance Food Group

Updated Category News Views 237

Understanding Performance Food Group's Growth Performance Food Group (NYSE: PFGC) has consistently impressed investors over the past decade. With an annualized performance exceeding the broader market by 3.61%, the company's average annual return has stood at a remarkable 16.06%. This outstanding growth underscores Performance Food Group's position as a significant player...

Continue Reading
Shell PLC's Market Sentiment: An Insightful Overview

Updated Category News Views 125

Understanding Shell PLC's Current Market Position Shell PLC's (NYSE: SHEL) stock performance is garnering attention from traders and investors alike. Recently, the company's short interest, calculated as a percentage of its float, has seen a notable decrease of 6.35%. Currently, there are 9.55 million shares that have been sold short, equating to 0.59% of the available...

Continue Reading
STEERBRIDGE Integrates Unanet ERP for Enhanced Operations

Updated Category News Views 261

STEERBRIDGE Partners with Unanet ERP for Operational Advancements In a significant move to enhance efficiency and support its federal contracting operations, STEERBRIDGE has made the strategic decision to utilize Unanet ERP. This shift aligns with the company's commitment to delivering innovative solutions that empower government agencies and improve mission delivery....

Continue Reading
Celebrating a New Era in the U.S. Toy Sector with The Toy Building

Updated Category News Views 373

A New Hub for the Toy Industry Recently, The Toy Association™ unveiled its new Toy Building, a remarkable milestone that reshapes the landscape of the toy industry. This state-of-the-art facility has been established in a bustling area known as the "Toy District," offering a dedicated space where toy companies, both big and small, can thrive and connect. The grand...

Continue Reading
Grupo Aeroportuario del Sureste Plans Annual Shareholders Meeting

Updated Category News Views 123

Grupo Aeroportuario del Sureste Plans Annual Shareholders Meeting Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR; BMV: ASUR), a prominent international airport group operating in various regions, has set the stage for its General Annual Ordinary Shareholders' Meeting. This important gathering will take place in the near future, focusing on various critical...

Continue Reading